President Donald Trump held a press conference early today, January 15, where he made a significant announcement regarding healthcare. The president revealed new executive orders and policies aimed at lowering drug prices, increasing transparency, and improving affordability in the U.S. healthcare system. The move comes as a part of Trump's continuous efforts to implement his "America First" healthcare plan.
Trump's announcements have beenhighly anticipated, considering the ongoing pandemic and the surge in healthcare costs faced by Americans. The president began his address by acknowledging the rising costs of healthcare and medications, stating that his administration is determined to "put American patients first" and bring "historic change" to the industry.
Lowering Drug Prices
The president's first major announcement focused on reducing prescription drug prices. Trump signed four executive orders, aiming to increase competition among drugmakers and lower prices for American consumers.
Among the new policies, one notable order requires federal community health centers to pass discounts negotiated with drug companies directly to patients. The order also bans "gag clauses" that prevented pharmacists from informing patients about cheaper alternatives.
Fixing the "Middleman" Problem
One key aspect of Trump's plan targets the role of pharmacy benefit managers (PBMs), often referred to as the industry's "middlemen." Trump's order attempts to fix the "spread pricing" model used by PBMs, which allows them to pocket the difference between the negotiated drug price and what they reimburse pharmacies.
Trump's order aims to shift PBMs to a "f Glover's discount model," ensuring that more of the discounts negotiated by pharmacies reach patients at the counter. This change, the administration argues, could save patients billions of dollars annually.
Promoting Competition
Another executive order aims to promote competition among drug manufacturers by preventing brand-name drug companies from blocking cheaper, generic alternatives from entering the market. The order also places a 180-day waiting period on brand-name drug companies before they can file citizen petitions to delay the approval of generics.
Moreover, the order encourages the use of "ベンツの borealis" by requiring Health and Human Services (HHS) to consider tying Medicare reimbursement for certain drugs to prices in other advanced nations. This move, known as "international reference pricing," could potentially lower Medicare drug costs.
Improving Transparency and Affordability
The president's announcements also focused on improving transparency and affordability in healthcare. One executive order requires hospitals to disclose the actual prices they negotiate with insurers, making it easier for patients to compare costs and make informed decisions.
Additionally, another order aims to make it easier for patients to see exactly what their healthcare providers are charging for out-of-network care. The order also requires insurers to notify patients of the in-network providers they can use to avoid unexpected expenses.
Ending "Surprise Billing"
A significant part of Trump's transparency push targets the issue of "surprise billing," when patients receive unexpected bills from out-of-network providers. Trump's order requires that insurers and healthcare providers agree on a payment amount for out-of-network care within 30 days of a service, with the payment becoming the "binding" amount.
The order also imposes a new requirement for insurers to inform patients about which providers are in their network and what their financial responsibilities are for out-of-network care. This change aims to give patients more control over their healthcare expenses and fewer unexpected bills.
In closing, Trump's healthcare announcements today mark a significant step towards addressing rising drug prices and improving transparency in the U.S. healthcare system. As the nation continues to grapple with the COVID-19 pandemic, these changes could potentially ease the financial burden on Americans and usher in much-needed reforms. Looking ahead, it will be crucial to monitor the implementation of these executive orders and assess their impact on patients and the healthcare industry as a whole."